PT-141: The Complete Guide
A cyclic heptapeptide that acts on melanocortin receptors in the brain — one of very few compounds studied in central neural pathways for sexual response research. FDA-approved as Vyleesi in 2019, with Phase 3 trial data and a substantial regulatory evidence base.
What is PT-141?
PT-141, also called Bremelanotide, is a small synthetic peptide — seven amino acids arranged in a closed ring. It's a refined cousin of Melanotan II, the peptide developed at the University of Arizona in the 1980s as a sunless tanning agent.
The way PT-141 was discovered is worth knowing. While researchers were studying Melanotan II in the 1980s, they noticed something unexpected: in addition to the pigmentation effects they were investigating, the compound seemed to produce arousal responses in study participants. That side observation redirected an entire research programme. Instead of pursuing tanning, scientists started investigating the brain pathways behind the unexpected effect, and PT-141 was eventually engineered as a refined compound focused on those pathways rather than on skin pigmentation.
Where PT-141 stands apart from most peptides in the research literature is where it works. Most compounds that affect sexual response in research models work peripherally — they act on blood vessels, similar to how Viagra-class drugs work. PT-141 works centrally, in the brain. Specifically, research suggests it activates melanocortin receptors called MC3R and MC4R, which are concentrated in the hypothalamus and limbic system — regions associated with motivation and arousal pathways. In simpler terms: rather than acting on the plumbing, it acts on the wiring.
This central mechanism is what makes PT-141 distinctive in the published literature. Research models that don't respond to peripheral compounds have shown measurable responses to PT-141, suggesting it's reaching a different system entirely.
PT-141 also has something rare in the peptide research space: full regulatory approval and Phase 3 clinical trial data. It was approved by the US FDA in 2019 under the brand name Vyleesi for premenopausal female subjects — one of the few research peptides with that depth of human safety and pharmacological evidence behind it.
Research Applications
PT-141 research spans melanocortin signalling, central nervous system arousal research, dopaminergic signalling pathways, and the broader α-MSH peptide family — one of the most extensively characterised neuropeptide families in the published literature.
Research suggests PT-141 acts on melanocortin receptors in the hypothalamus and limbic system — brain regions associated with motivation and arousal signalling. Research suggests this central pathway is the primary mechanism behind the observed effects in research models.
Research suggests that when PT-141 activates the MC4R receptor, dopamine release increases in a hypothalamic region called the medial preoptic area — a region linked to motivational signalling. The dopamine pathway is one of the proposed mechanisms behind PT-141’s observed research findings.
Approved in 2019 under the brand name Vyleesi — one of the few research peptides with full FDA regulatory approval and Phase 3 clinical trial data. This produces a substantial human safety and pharmacological evidence base that most research peptides do not have.
PT-141 is a research tool for studying melanocortin receptors — a family of brain receptors involved in pigmentation, appetite, energy regulation, and behaviour. Research on the melanocortin system has implications across multiple research areas.
Research suggests PT-141 produces measurable responses in research models without the peripheral or visual stimulation requirements associated with peripheral-acting compounds. This central-pathway distinction is one of the most-cited findings in the published PT-141 literature.
PT-141 has been evaluated in clinical trials across both male and female research populations, with FDA approval specifically for premenopausal female subjects. The cross-sex evidence base is one of the more comprehensive datasets in the melanocortin research family.
How PT-141 Works
Melanocortin receptor activation: PT-141 binds to two receptors called MC3R and MC4R. These are types of G protein-coupled receptors — a large family of receptors that sit in cell membranes and translate signals from outside the cell into actions inside it. The MC3R and MC4R receptors are densely concentrated in two brain regions: the hypothalamus and the limbic system, both of which are linked to motivational and arousal pathways. When PT-141 docks into these receptors, it triggers two downstream signalling chains called adenylyl cyclase and cAMP — biochemical messengers that, in plain terms, make the neurons in those regions more electrically responsive. The result is increased neuronal activity in brain regions tied to motivation and arousal.
Dopamine release: One of the downstream effects of MC4R activation is increased dopamine release in a small hypothalamic region called the medial preoptic area. Dopamine is the brain's "this matters" signalling chemical — it flags rewards, motivation, and salience. The medial preoptic area is the part of the hypothalamus that integrates hormonal and neural signals associated with sexual response. Research suggests this dopamine release is one of the key mechanisms behind PT-141's observed effects in the published literature.
Central pathway research: Most compounds studied for sexual response in research models work peripherally — they act on blood vessels, or they require visual or tactile triggers to produce effects. PT-141 doesn't. Research suggests it produces measurable responses purely through its central action on the brain, without needing peripheral stimulation. Early studies (Diamond et al. 2006, Molinoff et al. 2003) reported responses in research conditions where peripheral vascular agents produced no comparable effect. This central-mechanism distinction is one of the defining findings in the PT-141 research literature.
Cyclic structure: PT-141's seven amino acids aren't strung out in a line — they're joined into a closed ring, locked together by a chemical bridge between two of the amino acids (Asp and Lys). This ring shape matters because it makes the peptide much more stable than a linear chain of the same amino acids would be. Linear peptides get chewed up quickly by enzymes in the body; ring-shaped peptides resist that breakdown. Research suggests PT-141 has a half-life of around 2.7 hours, substantially longer than the natural melanocortin peptides the body produces, which contributes to its practical research profile.
Storage Guidelines
Store at 2–8°C in a cool, dry place. Protect from light and moisture. Refrigerate once in solution form.
Frequently Asked Questions
Technical Specifications
Compiled by the Southern Pacific Labs research team. Last updated April 2026.
Published References
- Diamond LE, Earle DC, Heiman JR, et al. “An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.” The journal of sexual medicine, 2006. PubMed
- Molinoff PB, Shadiack AM, Earle D, et al. “PT-141: a melanocortin agonist for the treatment of sexual dysfunction.” Annals of the New York Academy of Sciences, 2003. PubMed
- Kingsberg SA, Clayton AH, Portman D, et al. “Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.” Obstetrics and gynecology, 2019. PubMed
- Wikberg JE. “Melanocortin receptors: perspectives for novel drugs.” European journal of pharmacology, 1999. PubMed
Browse all PT-141 research on PubMed →
Related Research Guides
More in Melanocortin Research
A C-terminal tripeptide fragment of α-MSH targeting MC1R and broader melanocortin signalling — a fellow α-MSH-derived research compound, approached from the inflammation pathway rather than the central arousal pathway.
Read guide →Melanocortin AgonistThe parent peptide from which PT-141 was derived — a cyclic heptapeptide acting on multiple melanocortin receptors (MC1R, MC3R, MC4R, MC5R), originally developed for pigmentation research.
Read guide →Melanocortin AgonistA linear α-MSH analogue with selective MC1R activity — the first of the Melanotan family, distinguished from MT-2 and PT-141 by its receptor selectivity profile.
Read guide →